Antibiotics and is Bacteriostatic and Bactericidal

Satheesh Madhav*

Department of Pharmaceutics, DIT University, India

*Corresponding author: Satheesh Madhav, Department of Pharmaceutics, DIT University, India, Tel: + 91 9021317089; E-mail: madhavsth@gmail.com

Received: 7-Mar-2022, Manuscript No: JMPOPR-22-58340; Editor assigned: 9-Mar-2022, PreQC No: JMPOPR-22-58340(PQ); Reviewed: 16-Mar-2022, QC No: JMPOPR-22-58340; Revised: 21-Mar-2022, Manuscript No: JMPOPR-22-58340(R); Published: 28-Mar-2022, DOI: 10.4172/2329-9053.1000131

Citation: Madhav S (2022) Antibiotics and is Bacteriostatic and Bactericidal. J Mol Pharm Org Process Res 10: 131.

Copyright: © 2022 Madhav S. This is an open-access article distributed under synthetic sulpha medicines. Since then, several antibiotic classes with varied antimicrobial properties have been found, allowing them to be used empirically or in specic clinical circumstances. Antibiotics can be bactericidal or bacteriostatic depending on their method of action. Multiple trials, however, have found little clinical relevance between tidal and static antibiotics. eir existence has resulted in

References

- Mocroft A, Vella S, Benfeld TL, Chiesi A, Miller V, et al. (1998) Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 352:1725–1730.
- Forrest GN, Tamura K (2010) Rifampin combination therapy for nonmycobacterial infections. Clin. Microbiol. Rev 23:14–34.
- Johansen HK, Jensen TG, Dessau RB, Lundgren B, Frimodt-Moller N (2000)
 Antagonism between penicillin and erythromycin against Streptococcus pneumoniae in vitro and in vivo. J. Antimicrob. Chemother. 46:973–980.
- Falagas ME, Grammatikos AP, Michalopoulos A (2008) Potential of oldgeneration antibiotics to address current need for new antibiotics. Expert Rev Anti Infect Ther 6:593–600.
- Lázár V, Pal Singh G, Spohn R, Nagy I, Horváth B, et al. (2013) Bacterial evolution of antibiotic hypersensitivity. Mol Syst Biol 9:700.

- Drusano GL, D'Argenio DZ, Symonds W, Bilello PA, McDowell J, et al. (1998) Nucleoside analog 1592U89 and human immunodefciency virus protease inhibitor 141W94 are synergistic in vitro. Antimicrob Agents Chemother 42:2153–2159.
- Wang P, Robert L, Pelletier J, Dang WL, Taddei F, et al. (2010) Robust growth of Escherichia coli. Curr Biol 20:1099–1103.
- Eng RHK, Padberg FT, Smith SM, Tan EN, Cherubin CE (1991) Bactericidal efects of antibiotics on slowly growing and nongrowing bacteria. Antimicrob Agents Chemother 35:1824–1828.
- King DE, Malone R, Lilley SH (2000) New classification and update on the quinolone antibiotics. American Family Physician 61:2741-2748.
- Emami S, Shafee A, Foroumadi A (2005) Quinolones: Recent structural and clinical developments. Iranian Journal of Pharmaceutical Research 4:123-136.